Acquired resistance to selective FGFR inhibitors in FGFR-altered cholangiocarcinoma

被引：0
|
作者：
Goyal, L. [1 ]
Baiev, I. [1 ]
Zhang, K. [2 ]
Dalgai, S. [3 ]
Shroff, R. T. [4 ]
Kelley, R. K. [2 ]
Uboha, N. [5 ]
机构：
[1] Massachusetts Gen Hosp, Gastrointestinal Oncol, Boston, MA 02114 USA
[2] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Gastrointestinal Oncol, San Francisco, CA 94143 USA
[3] Univ Arizona, Dept Med, Coll Med, Tucson, AZ USA
[4] Univ Arizona, Div Hematol & Oncol, Coll Med, Tucson, AZ USA
[5] Univ Wisconsin, Div Hematol & Oncol, Carbone Canc Ctr, Madison, WI USA
来源：
EUROPEAN JOURNAL OF CANCER | 2020年 / 138卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
49
引用
收藏
页码：S21 / S22
页数：2
相关论文
共 50 条
  • [21] Effect of FGFR alteration on prognosis in 1963 urothelial carcinoma patients with immune checkpoint inhibitors: Implying combination of FGFR inhibitor and immunotherapy for FGFR-altered urothelial carcinoma
    Song, Yuxuan
    Jiang, Shan
    Peng, Yun
    Qin, Caipeng
    Du, Yiqing
    Xu, Tao
    PHARMACOLOGICAL RESEARCH, 2024, 205
  • [22] Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 Alterations
    Varghese, Anna M.
    Patel, Juber
    Janjigian, Yelena Y.
    Meng, Fanli
    Selcuklu, S. Duygu
    Iyer, Gopakumar
    Houck-Loomis, Brian
    Harding, James J.
    O'Reilly, Eileen M.
    Abou-Alfa, Ghassan K.
    Lowery, Maeve A.
    Berger, Michael F.
    JCO PRECISION ONCOLOGY, 2021, 5 : 44 - 50
  • [23] CLINICAL CHARACTERIZATION OF FGFR-ALTERED, PEDIATRIC LOW-GRADE GLIOMAS
    Posorske, Benjamin
    Tiwari, Nishant
    Keller, Lisa
    Dorris, Kathleen
    Goldman, Stewart
    Hoffman, Lindsey M.
    Mangum, Ross
    NEURO-ONCOLOGY, 2024, 26
  • [24] Targeting COPA to Enhance Erdafitinib Sensitivity in FGFR-Altered Bladder Cancer
    Zhao, Huayuan
    Gao, Xincheng
    Jiang, Yangkai
    Yu, Yanchao
    Wang, Liang
    Sun, Jiayin
    Wang, Miao
    Xiong, Xing
    Huang, Chao
    Zhang, Hui
    Jiang, Guosong
    ADVANCED SCIENCE, 2025,
  • [25] Resistance mechanism to fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma
    Lamarca, Angela
    Ostios, Lorena
    Mcnamara, Mairead G.
    Garzon, Carlos
    Gleeson, Jack P.
    Edeline, Julien
    Herrero, Ana
    Hubner, Richard A.
    Moreno, Victor
    Valle, Juan W.
    CANCER TREATMENT REVIEWS, 2023, 121
  • [26] Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies
    Facchinetti, Francesco
    Loriot, Yohann
    Braye, Floriane
    Vasseur, Damien
    Bahleda, Rastislav
    Bigot, Ludovic
    Barbe, Remy
    Nobre, Catline
    Combarel, David
    Michiels, Stefan
    Italiano, Antoine
    Smolenschi, Cristina
    Tselikas, Lambros
    Scoazec, Jean-Yves
    Ponce-Aix, Santiago
    Besse, Benjamin
    Andre, Fabrice
    Olaussen, Ken A.
    Hollebecque, Antoine
    Friboulet, Luc
    CLINICAL CANCER RESEARCH, 2024, 30 (21) : 4943 - 4956
  • [27] Understanding and overcoming resistance to selective FGFR inhibitors across FGFR2-driven tumors
    Facchinetti, F.
    Loriot, Y.
    Braye, F.
    Vasseur, D.
    Bahleda, R.
    Bigot, L.
    Barbe, R.
    Nobre, C.
    Combarel, D.
    Michiels, S.
    Italiano, A.
    Smolenschi, C.
    Tselikas, L.
    Scoazec, J.
    Aix, S. Ponce
    Besse, B.
    Andre, F.
    Olaussen, K. A.
    Hollebecque, A.
    Friboulet, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S291 - S292
  • [28] Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma
    Goyal, Lipika
    Saha, Supriya K.
    Liu, Leah Y.
    Siravegna, Giulia
    Leshchiner, Ignaty
    Ahronian, Leanne G.
    Lennerz, Jochen K.
    Vu, Phuong
    Deshpande, Vikram
    Kambadakone, Avinash
    Mussolin, Benedetta
    Reyes, Stephanie
    Henderson, Laura
    Sun, Jiaoyuan Elisabeth
    Van Seventer, Emily E.
    Gurski, Joseph M., Jr.
    Baltschukat, Sabrina
    Schacher-Engstler, Barbara
    Barys, Louise
    Stamm, Christelle
    Furet, Pascal
    Ryan, David P.
    Stone, James R.
    Iafrate, A. John
    Getz, Gad
    Porta, Diana Graus
    Tiedt, Ralph
    Bardelli, Alberto
    Juric, Dejan
    Corcoran, Ryan B.
    Bardeesy, Nabeel
    Zhu, Andrew X.
    CANCER DISCOVERY, 2017, 7 (03) : 252 - 263
  • [29] Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapy
    Benjamin, David J.
    Hsu, Robert
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [30] Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in FGFR2 fusion-positive cholangiocarcinoma patients
    Goyal, Lipika
    Saha, Supriya K.
    Liu, Leah Y.
    Siravegna, Giulia
    Leshchiner, Ignaty
    Ahronian, Leanne G.
    Lennerz, Jochen K.
    Phuong Vu
    Mussolin, Benedetta
    Reyes, Stephanie
    Furet, Pascal
    Iafrate, A. John
    Getz, Gad
    Porta, Diana G.
    Tiedt, Ralph
    Bardelli, Alberto
    Juric, Dejan
    Corcoran, Ryan B.
    Bardeesy, Nabeel
    Zhu, Andrew X.
    CANCER RESEARCH, 2017, 77
12345